Erratum: Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience (The Oncologist (2006) 11 (73-82) DOI: 10.1634/theoncologist.11-1-73);Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience

Oncologist

Volumn 11, Issue 1, 2006, Pages 73-82

  Quirt, Ian ^a   Kovacs, Michael ^b   Couture, Félix ^c,d   Turner, A Robert ^e   Noble, Michael ^f   Burkes, Ronald ^g   Dolan, Sean ^h   Plante, Richard K ⁱ   Lau, Catherine Y ⁱ   Chang, José ^j  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c Hotel Dieu de Levis Hospital   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

^f ROYAL COLUMBIAN HOSPITAL   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

^h SAINT JOHN REGIONAL HOSPITAL   (Canada)

ⁱ Janssen Ortho Inc   (Canada)

^j LAKERIDGE HEALTH CORPORATION   (Canada)

more..

Author keywords

Anemia management; Epoetin alfa; Transfusion risk predictors

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANADA; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; VALIDATION STUDY;

EID: 31444447968     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-4-420     Document Type: Erratum

References (36)

1. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-2320.
2. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003;43:1007-1017.
3. Pealer LN, Marfin AA, Petersen LR et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003;349:1236-1245.
4. Hart J, Leier B, Nahirniak S. Informed consent for blood transfusion: should the possibility of prior risk be included? Transfus Med Rev 2004;18:177-183.
5. Groopman JE, Itri LM. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
6. Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep 2004;6:297-304.
7. Ludwig H, Birgegard G, Barrett-Lee P et al. Prevalence and management of anemia in patients with hematologic malignancies and solid tumours: results from the European Cancer Anemia Survey (ECAS). Blood 2002;100:234a-235a.
8. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985;85:7580-7584.
9. Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998;25(suppl 7):35-38.
10. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebocontrolled trial. J Clin Oncol 2001;19:2865-2874.
11. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992;87(suppl 1):4-11.
12. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
13. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
14. Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin-́ increases hemoglobin and improves quality of life in anemic patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
15. Demetri GD, Gabrilove JL, Blasi MV et al. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002;3:45-51.
16. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
17. Platanias LC, Miller CB, Mick R et al. Treatment of chemotherapyinduced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-2026.
18. Ludwig H, Sundal E, Pecherstorfer M et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76:2319-2329.
19. Cortesi E, Mancuso A, De Pasquale Ceratti A et al. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy. The Oncologist 2004;9:459-468.
20. Patton J, Kuzur M, Liggett W et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every three weeks increases and maintains haemoglobin levels in anemic cancer patients undergoing chemotherapy. The Oncologist 2004;9:90-96.
21. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol 2001;113:172-179.
22. Ferrario E, Ferrari L, Bidoli P et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-575.
23. Quirt I, Robeson C, Lau CY et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
24. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-2605.
25. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.
26. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology, v.2, 2004. Cancer- and treatment-related anemia. NCCN, 2004. Available at http://www.nccn.org/professional/physician_gls/ PDF/anemia.pdf
27. Savonije JH, van Groeningen CJ, van Bochove A et al. Early intervention with epoetin alfa during platinum based chemotherapy. Proc Am Soc Clin Oncol 2004;22:8111.
28. Balducci L, Extermann M. Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am 2000;14:1-16.
29. Repetto L, Carreca I, Maraninchi D et al. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 2003;45:123-128.
30. Barrett-Lee PJ, Bailey NP, O'Brien ME et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-97.
31. Couture F, Turner AR, Melosky B et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. The Oncologist 2005;10:63-71.
32. Gisselbrecht C, Tesch H, Jourdan E et al. Cognitive effects of once weekly epoetin alfa in anemic patients with hematologic malignancies receiving chemotherapy: interim results of the EPOLYM trial. Blood 2004;104:2217a.
33. SAS/STAT® User's Guide, Version 6, Fourth Edition, Volume 2. Cary, NC: SAS Institute Inc., 1990:1071-1126.
34. Bohlius J, Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-498.
35. Hopkins SP, Bastianelli P, Cheung WK. Hemoglobin response of cancer patients with epoetin alfa: the Ottawa Hospital, Integrated Cancer Program experience. Presented at Canadian Society of Hospital Pharmacists, February 2005.
36. Tyono I, Moore C, Rashid F et al. A pharmacist-initiated hemoglobin monitoring program: a pilot program identifying patients with chemotherapy-related anemia in a community oncology setting. Presented at Canadian Society of Hospital Pharmacists, February 2005.